LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE.

LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE.

Background And Objectives: Chronic active Epstein-Barr virus infection (CAEBV) is a lymphoproliferative disorder characterized by the increased numbers of EBV-infected T/natural killer (NK) cells and ongoing symptoms resembling infectious mononucleosis. Nonetheless, the exact correlation between pe...

Full description

Saved in:

Bibliographic Details
Main Author:	kang sun
Format:	Article
Language:	English
Published:	PAGEPress Publications 2024-04-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	chronic active Epstein-Barr virus lymphocyte subsets programmed cell death protein 1 programmed death-ligand 1 helper T cells 1 helper T cells 2
Online Access:	https://www.mjhid.org/mjhid/article/view/5551
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients
by: Eman Eissa, et al.
Published: (2022-01-01)

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
by: Hanan R. Nada, et al.
Published: (2025-01-01)

Beyond immortality: Epstein–Barr virus and the intricate dance of programmed cell death in cancer development
by: Arezoo Esmaeili, et al.
Published: (2024-01-01)

PLUNC downregulates the expression of PD-L1 by inhibiting the interaction of DDX17/β-catenin in nasopharyngeal carcinoma
by: Ranran Feng, et al.
Published: (2025-01-01)

Preclinical evaluation and preliminary clinical study of 68Ga-NODAGA-NM-01 for PET imaging of PD-L1 expression
by: Lingzhou Zhao, et al.
Published: (2025-01-01)

The trend of Epstein-Barr virus DNA loads and CD8+ T lymphocyte numbers can predict the prognosis of pediatric liver transplant recipients with PTLD
by: Wang Kedi, et al.
Published: (2025-02-01)

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
by: Jie Fu, et al.
Published: (2025-01-01)

Therapeutic implications for the PD-1 axis in cerebrovascular injury
by: James Feghali, et al.
Published: (2025-01-01)

Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma
by: Xueling Shi, et al.
Published: (2025-12-01)

Correlation analysis of DLG5 and PD-L1 expression in triple-negative breast cancer
by: Jingmin Che, et al.
Published: (2025-01-01)

Timosin alpha-1 immunomodulating properties
by: M. V. Mayevskaya
Published: (2009-02-01)

Interplay of aurora kinase a functional residues and Epstein-barr Nuclear Antigen 1 in Epstein-barr virus associated Gastric cancer using AGS cells
by: Nidhi Varshney, et al.
Published: (2025-01-01)

C5a/C5aR regulates Th1/Th2 imbalance in sepsis-associated lung injury by promoting neutrophil activation to increase PAD4 expression
by: Zhenbing Lu, et al.
Published: (2025-12-01)

Innovative CDR grafting and computational methods for PD-1 specific nanobody design
by: Jagadeeswara Reddy Devasani, et al.
Published: (2025-01-01)

Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade
by: Cheng Xu, et al.
Published: (2023-04-01)

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01)

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
by: Kun Du, et al.
Published: (2025-02-01)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis
by: Huimin Zhao, et al.
Published: (2025-02-01)

Programmed Cell Death Ligand 1 (PD-L1) and major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in triple-Negative Breast Cancer
by: Kaewkedsri P, et al.
Published: (2025-02-01)

Programmed cell death 1 inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma: a single-center experience
by: Xing Huang, et al.
Published: (2024-12-01)

Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials
by: Nikolas Naleid, et al.
Published: (2025-01-01)

RIPK1 in necroptosis and recent progress in related pharmaceutics
by: Kunhou Yao, et al.
Published: (2025-02-01)

PRESENCIA DEL MARCADOR LMP-1 DEL VIRUS EPSTEIN-BARR EN LINFOMAS DE CANINOS
by: L. C. Veloza, et al.
Published: (2017-01-01)

Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report
by: Linchuan Li, et al.
Published: (2025-01-01)

A conserved element in the first intron of Cd4 has a lineage specific, TCR signal-responsive, canonical enhancer function that matches the timing of cell surface CD4 upregulation required to prevent lineage choice error
by: Gregory A. Swan, et al.
Published: (2025-01-01)

Prognostic value of tumor‐infiltrating lymphocytes and PD‐L1 expression in esophageal squamous cell carcinoma
by: Jie Hu, et al.
Published: (2024-09-01)

Plasma Epstein-Barr Virus DNA load for diagnostic and prognostic assessment in intestinal Epstein-Barr Virus infection
by: Chunxiang Ma, et al.
Published: (2025-01-01)

Colorimetric aptasensor coupled with a deep-learning-powered smartphone app for programmed death ligand-1 expressing extracellular vesicles
by: Adeel Khan, et al.
Published: (2025-01-01)

Role of Computed Tomography in Predicting Programmed Death Ligand-1 Positivity in Gastric Adenocarcinoma
by: Yu ZH, et al.
Published: (2025-02-01)

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01)

Computational biology assisted exploration of phytochemicals derived natural inhibitors to block BZLF1 gene activation of Epstein–Bar virus in host
by: Muhammad Naveed, et al.
Published: (2024-12-01)

Infarct‐like myocarditis with coronary vasculitis and aneurysm formation caused by Epstein–Barr virus infection
by: Cristina Chimenti, et al.
Published: (2020-06-01)

Deciphering the Differences Between Epstein–Barr Virus‐Associated and Negative Gastric Cancer in the Prospect of CDKN2A Genomic Alterations and Lymphoid Infiltration
by: Fuda Xie, et al.
Published: (2025-01-01)

Expression of serum miR‐135a in patients with allergic rhinitis and its relationship with Treg/Th17 balance
by: Jing Cai, et al.
Published: (2025-01-01)

Problems of creating antibody phage libraries and their solutions
by: V. S. Aripov, et al.
Published: (2024-04-01)

The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2
by: Huanhuan Yan, et al.
Published: (2025-02-01)

Age-related immunosenescence and Epstein–Barr virus-positive mucocutaneous ulcer presenting as oral cancer: a case report
by: Jiayuan Ye, et al.
Published: (2025-01-01)

Structure- and machine learning-guided engineering demonstrate that a non-canonical disulfide in an anti-PD-1 rabbit antibody does not impede antibody developability
by: Wei-Ching Liang, et al.
Published: (2024-12-01)

Retrospective Investigation of Cytomegalovirus and Epstein–Barr Virus Positivity in Inflammatory Bowel Disease Patient Biopsies
by: Hasan Bostancı, et al.
Published: (2024-01-01)

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma
by: Mengdi Fu, et al.
Published: (2025-02-01)